**S6 Table. Associations between fibrinolytic therapy and the risk of short-term major adverse cardiovascular events among patients with and without chronic kidney disease (eGFR <60 mL/min/1.73 m2), results of propensity score-matched subgroup**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | eGFR ≥60 mL/min/1.73 m2 (n=5502) | | eGFR <60 mL/min/1.73 m2 (n=588) | | *P* for interaction |
|  | RR (95% CI) | *P* value | RR (95% CI) | *P* value |
| Model 1\* |  |  |  |  |  |
| No fibrinolysis | Ref | / | Ref | / | / |
| Fibrinolysis | 0.80 (0.60 to 1.06) | 0.126 | 1.02 (0.69 to 1.51) | 0.920 | 0.158 |
| Model 2† |  |  |  |  |  |
| No fibrinolysis | Ref | / | Ref | / |  |
| Fibrinolysis | 0.78 (0.58 to 1.04) | 0.092 | 0.99 (0.67 to 1.47) | 0.978 | 0.152 |

\*Adjusted for age, sex, intervention, cycle, fibrin-specific thrombolytic agent, delay to admission, and delay to fibrinolytic therapy.

†Further adjusted for propensity scores.

eGFR, estimated glomerular filtration rate; RR, relative risk; CI, confidence interval.